
Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma
Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma.
Read the full article:
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Mais episódios de "The Lancet Haematology in conversation with"
Não percas um episódio de “The Lancet Haematology in conversation with” e subscrevê-lo na aplicação GetPodcast.